JPWO2019197842A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019197842A5 JPWO2019197842A5 JP2020555420A JP2020555420A JPWO2019197842A5 JP WO2019197842 A5 JPWO2019197842 A5 JP WO2019197842A5 JP 2020555420 A JP2020555420 A JP 2020555420A JP 2020555420 A JP2020555420 A JP 2020555420A JP WO2019197842 A5 JPWO2019197842 A5 JP WO2019197842A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- quinoline
- oxazepino
- chloro
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DDNHKOMVKLDTQY-UHFFFAOYSA-N 7H-quinolin-6-one Chemical compound N1=CC=CC2=CC(CC=C12)=O DDNHKOMVKLDTQY-UHFFFAOYSA-N 0.000 claims 64
- 125000000217 alkyl group Chemical group 0.000 claims 51
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 47
- 229910052739 hydrogen Inorganic materials 0.000 claims 41
- 239000001257 hydrogen Substances 0.000 claims 37
- -1 cyano, acetylenyl Chemical group 0.000 claims 35
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims 21
- 125000001188 haloalkyl group Chemical group 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 19
- 239000012453 solvate Substances 0.000 claims 19
- 125000001424 substituent group Chemical group 0.000 claims 19
- 125000005843 halogen group Chemical group 0.000 claims 18
- ZVBZUYIYZHXAFY-UHFFFAOYSA-N 1,7-dihydrooxazepino[6,5-c]quinoline-5,6-dione Chemical compound C1C=NOC(C=2C(NC=3C=CC=CC=3C=21)=O)=O ZVBZUYIYZHXAFY-UHFFFAOYSA-N 0.000 claims 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims 16
- 125000004438 haloalkoxy group Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 150000002431 hydrogen Chemical group 0.000 claims 9
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 229910005965 SO 2 Inorganic materials 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001246 bromo group Chemical group Br* 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims 4
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- SZCKSNPRMHFNIV-UHFFFAOYSA-N 2-ethyloctanamide Chemical compound CCCCCCC(CC)C(N)=O SZCKSNPRMHFNIV-UHFFFAOYSA-N 0.000 claims 2
- NDCQPJCNZBQYAO-UHFFFAOYSA-N 4-[[3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(C=2C3=CC=CC(=C3N=CC=2C(=O)C=2C=CC=CC=2)C(F)(F)F)=C1 NDCQPJCNZBQYAO-UHFFFAOYSA-N 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 229940081066 picolinic acid Drugs 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- HGIIOSISILPQAD-QEEYODRMSA-N (2R)-10-[[5-chloro-2-[(3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl]pyrimidin-4-yl]amino]-2-cyclopropyl-7-methyl-1,2,3,4-tetrahydro-[1,4]thiazepino[2,3-c]quinolin-6-one Chemical compound ClC=1C(=NC(=NC=1)N1C[C@@H](C([C@@H](C1)C)(F)F)C)NC1=CC=2C3=C(C(N(C=2C=C1)C)=O)SCC[C@@H](N3)C1CC1 HGIIOSISILPQAD-QEEYODRMSA-N 0.000 claims 1
- LCMPNVYSMTYYJE-UHFFFAOYSA-N 2-chloro-4-[(2,7-dimethyl-5,6-dioxo-1,2,3,4-tetrahydro-[1,4]diazepino[6,5-c]quinolin-10-yl)amino]pyridine-3-carbonitrile Chemical compound ClC1=C(C#N)C(=CC=N1)NC1=CC=2C3=C(C(N(C=2C=C1)C)=O)C(NCC(N3)C)=O LCMPNVYSMTYYJE-UHFFFAOYSA-N 0.000 claims 1
- CPRJDQUHIKJKEF-UHFFFAOYSA-N 2-chloro-4-[(2,7-dimethyl-6-oxospiro[2,4-dihydro-1H-[1,4]oxazepino[2,3-c]quinoline-3,1'-cyclopropane]-10-yl)amino]pyridine-3-carbonitrile Chemical compound ClC1=C(C#N)C(=CC=N1)NC1=CC=2C3=C(C(N(C=2C=C1)C)=O)OCC1(C(N3)C)CC1 CPRJDQUHIKJKEF-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- GCNQKCIUMOPHPN-UHFFFAOYSA-N O=C1C=C(C=CN=N2)C2=CC1 Chemical compound O=C1C=C(C=CN=N2)C2=CC1 GCNQKCIUMOPHPN-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 125000006193 alkinyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024082277A JP2024119835A (ja) | 2018-04-13 | 2024-05-21 | Ｂｃｌ６阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1806132.5 | 2018-04-13 | ||
| GBGB1806132.5A GB201806132D0 (en) | 2018-04-13 | 2018-04-13 | Inhibitor coumpounds |
| GB1819136.1 | 2018-11-23 | ||
| GBGB1819136.1A GB201819136D0 (en) | 2018-11-23 | 2018-11-23 | Inhibitor compounds |
| PCT/GB2019/051058 WO2019197842A1 (en) | 2018-04-13 | 2019-04-12 | Bcl6 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024082277A Division JP2024119835A (ja) | 2018-04-13 | 2024-05-21 | Ｂｃｌ６阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521165A JP2021521165A (ja) | 2021-08-26 |
| JPWO2019197842A5 true JPWO2019197842A5 (ru) | 2022-02-07 |
| JP7493454B2 JP7493454B2 (ja) | 2024-05-31 |
Family
ID=66240166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555420A Active JP7493454B2 (ja) | 2018-04-13 | 2019-04-12 | Ｂｃｌ６阻害剤 |
| JP2024082277A Pending JP2024119835A (ja) | 2018-04-13 | 2024-05-21 | Ｂｃｌ６阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024082277A Pending JP2024119835A (ja) | 2018-04-13 | 2024-05-21 | Ｂｃｌ６阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11512095B2 (ru) |
| EP (2) | EP4201939A1 (ru) |
| JP (2) | JP7493454B2 (ru) |
| KR (1) | KR20200144109A (ru) |
| CN (1) | CN112334475B (ru) |
| AU (2) | AU2019253510B2 (ru) |
| BR (1) | BR112020020832A2 (ru) |
| CA (1) | CA3095371A1 (ru) |
| DK (1) | DK3774817T3 (ru) |
| ES (1) | ES2939776T3 (ru) |
| HR (1) | HRP20230120T1 (ru) |
| IL (2) | IL296734A (ru) |
| MX (2) | MX2020010805A (ru) |
| PT (1) | PT3774817T (ru) |
| SG (1) | SG11202009735QA (ru) |
| WO (1) | WO2019197842A1 (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019253510B2 (en) * | 2018-04-13 | 2023-08-10 | Cancer Research Technology Limited | BCL6 inhibitors |
| GB201909573D0 (en) | 2019-07-03 | 2019-08-14 | Cancer Research Tech Ltd | Modulation of T cell cytotoxicity and related therapy |
| GB201914860D0 (en) * | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| US20220323457A1 (en) * | 2019-10-17 | 2022-10-13 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| WO2022221673A1 (en) | 2021-04-16 | 2022-10-20 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| TW202415665A (zh) | 2022-06-06 | 2024-04-16 | 美商樹線生物科學公司 | 三環喹啉酮ｂｃｌ６雙功能降解劑 |
| WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| TW202415655A (zh) | 2022-06-13 | 2024-04-16 | 美商樹線生物科學公司 | １，８—萘啶—２—酮異雙功能ｂｃｌ６降解劑 |
| WO2024019995A1 (en) * | 2022-07-19 | 2024-01-25 | Dana-Farber Cancer Institute, Inc. | Quinoxalinedione and pyrido [2, 3-b]pyrazine-2, 3-dione b cell lymphoma 6 (bcl6) degraders and uses thereof |
| WO2024193464A1 (zh) * | 2023-03-17 | 2024-09-26 | 西藏海思科制药有限公司 | 一种含氮三并环衍生物及其在医药上的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| ES2194181T3 (es) | 1996-02-13 | 2003-11-16 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de vegf. |
| DK0885198T3 (da) | 1996-03-05 | 2002-03-25 | Astrazeneca Ab | 4-Anilinoquinazolinderivater |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| RU2262935C2 (ru) | 1999-02-10 | 2005-10-27 | Астразенека Аб | Производные хиназолина в качестве ингибиторов ангиогенеза |
| US7030123B2 (en) | 2000-05-31 | 2006-04-18 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (ru) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хиназолиновые производные для лечения опухолей и фармацевтическая композиция |
| AU6623201A (en) | 2000-07-07 | 2002-02-05 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| US8815891B2 (en) * | 2008-11-11 | 2014-08-26 | Je Il Pharmaceutical Co., Ltd. | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
| JP2016510051A (ja) | 2013-03-05 | 2016-04-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトン型チロシンキナーゼの阻害剤 |
| US9943506B2 (en) | 2013-06-17 | 2018-04-17 | Cornell University | BCL6 inhibitors as anticancer agents |
| JP6999688B2 (ja) | 2016-12-13 | 2022-02-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｃｌ６阻害剤としての新規の６－アミノキノリノン化合物および誘導体 |
| WO2018215798A1 (en) * | 2017-05-26 | 2018-11-29 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
| KR102628675B1 (ko) | 2017-05-26 | 2024-01-25 | 캔써 리서치 테크놀로지 리미티드 | 벤즈이미다졸론 유래된 bcl6의 저해제 |
| AU2019253510B2 (en) * | 2018-04-13 | 2023-08-10 | Cancer Research Technology Limited | BCL6 inhibitors |
-
2019
- 2019-04-12 AU AU2019253510A patent/AU2019253510B2/en active Active
- 2019-04-12 MX MX2020010805A patent/MX2020010805A/es unknown
- 2019-04-12 IL IL296734A patent/IL296734A/en unknown
- 2019-04-12 CA CA3095371A patent/CA3095371A1/en active Pending
- 2019-04-12 SG SG11202009735QA patent/SG11202009735QA/en unknown
- 2019-04-12 BR BR112020020832-9A patent/BR112020020832A2/pt unknown
- 2019-04-12 CN CN201980039513.4A patent/CN112334475B/zh active Active
- 2019-04-12 WO PCT/GB2019/051058 patent/WO2019197842A1/en active Application Filing
- 2019-04-12 EP EP22211485.2A patent/EP4201939A1/en active Pending
- 2019-04-12 HR HRP20230120TT patent/HRP20230120T1/hr unknown
- 2019-04-12 JP JP2020555420A patent/JP7493454B2/ja active Active
- 2019-04-12 KR KR1020207032149A patent/KR20200144109A/ko not_active Application Discontinuation
- 2019-04-12 PT PT197188345T patent/PT3774817T/pt unknown
- 2019-04-12 ES ES19718834T patent/ES2939776T3/es active Active
- 2019-04-12 EP EP19718834.5A patent/EP3774817B1/en active Active
- 2019-04-12 DK DK19718834.5T patent/DK3774817T3/da active
- 2019-04-12 US US17/046,650 patent/US11512095B2/en active Active
-
2020
- 2020-10-04 IL IL277778A patent/IL277778B2/en unknown
- 2020-10-12 MX MX2023004920A patent/MX2023004920A/es unknown
-
2022
- 2022-10-18 US US17/968,159 patent/US20230287003A1/en active Pending
-
2023
- 2023-11-09 AU AU2023263501A patent/AU2023263501A1/en active Pending
-
2024
- 2024-05-21 JP JP2024082277A patent/JP2024119835A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230120T1 (hr) | Inhibitori bcl6 | |
| RU2473549C2 (ru) | Пиримидиновые соединения, композиции и способы применения | |
| AU2022325858A1 (en) | Heterocyclic compounds and methods of use | |
| JP2015521600A5 (ru) | ||
| JP2019535664A5 (ru) | ||
| JPWO2020081848A5 (ru) | ||
| JP2024532735A (ja) | 複素環式化合物及び使用方法 | |
| JP2024532734A (ja) | 複素環式化合物及び使用方法 | |
| AU2022265682A1 (en) | 2-aminobenzothiazole compounds and methods of use thereof | |
| RU2019115115A (ru) | Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7 | |
| US20200339603A1 (en) | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | |
| JP2024517695A (ja) | 複素環式化合物及び使用方法 | |
| SI3083625T1 (en) | Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors | |
| JP2016518372A5 (ru) | ||
| US20230143612A1 (en) | Substituted 1,1'-biphenyl compounds and methods using same | |
| JPWO2019197842A5 (ru) | ||
| JP2005519086A5 (ru) | ||
| CA2474823A1 (en) | Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | |
| AU2023221732A1 (en) | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins | |
| WO2023159086A1 (en) | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins | |
| JPWO2020207991A5 (ru) | ||
| CN117897159A (zh) | 杂环化合物及使用方法 | |
| CN117835976A (zh) | 杂环化合物及使用方法 | |
| RU2021131710A (ru) | Соединения гексагидро-1h-пиразино[1,2-a]пиразина для лечения аутоиммунного заболевания | |
| WO2024229317A1 (en) | Spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof |